CYP2A13 Polyclonal Antibody

Rabbit Anti-CYP2A13 Polyclonal Antibody

Product Specifications

Background

CYP2A13 encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum. Although its endogenous substrate has not been determined, it is known to metabolize 4- (methylnitrosamino) -1- (3-pyridyl) -1-butanone, a major nitrosamine specific to tobacco. CYP2A13 is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q.

CAS Number

9007-83-4

Product Name Alternative

CYP2A13; Cytochrome P450 2A13; CYPIIA13

Gene ID

1553

Accession Number

Q16696

Reactivity

Human

Immunogen

Synthesized peptide derived from the Internal region of human CYP2A13 at AA range: 280-360

Clonality

Polyclonal

Tag

Cytochrome P450 2A13

Applications

WB, IHC, IF, ELISA

Purification Method

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration

1 mg/ml

Molecular Weight

56kD

Precautions

The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Shipping Conditions

Gel pack with blue ice.

Storage Conditions

Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Notes

CYP2A13 Polyclonal Antibody detects endogenous levels of CYP2A13 protein.

Observed Molecular Weight

Formulation

Liquid solution

Buffer pH

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Applications Notes

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:20000; Not yet tested in other applications.